Shandong Boan Biotechnology Co. Ltd. Receives FDA Approval to Initiate Clinical Trials for BA1302 in the U.S

Reuters

2025/06/17

Shandong Boan Biotechnology Co. Ltd. Receives FDA Approval to Initiate Clinical Trials for BA1302 in the U.S

Shandong Boan Biotechnology Co. Ltd. has announced that it has received approval from the U.S. Food and Drug Administration (FDA) to initiate clinical trials for its novel antibody-drug conjugate $(ADC)$, BA1302, targeting CD228 for the treatment of various solid tumors. BA1302 has previously been granted Orphan Drug Designations by the FDA for squamous non-small cell lung cancer and pancreatic cancer. Currently, a Phase 1 clinical trial is ongoing in China, with development progress leading similar projects globally. The company is committed to accelerating the clinical development of BA1302 worldwide, aiming to explore its potential as a monotherapy and in combination with other treatments, thereby offering new hope for targeted cancer treatment. This announcement marks a significant step forward in Shandong Boan Biotechnology's efforts to provide innovative cancer therapies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief on June 17, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2544090939"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2544090939\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2544090939?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-17 12:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544090939","market":"fut","top_or_hot":-1,"title":"Shandong Boan Biotechnology Co. Ltd. Receives FDA Approval to Initiate Clinical Trials for BA1302 in the U.S","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Shandong Boan Biotechnology Co. Ltd. Receives FDA Approval to Initiate Clinical Trials for BA1302 in the U.S\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Shandong Boan Biotechnology Co. Ltd. has announced that it has received approval from the U.S. Food and Drug Administration (FDA) to initiate clinical trials for its novel antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>, BA1302, targeting CD228 for the treatment of various solid tumors. BA1302 has previously been granted Orphan Drug Designations by the FDA for squamous non-small cell lung cancer and pancreatic cancer. Currently, a Phase 1 clinical trial is ongoing in China, with development progress leading similar projects globally. The company is committed to accelerating the clinical development of BA1302 worldwide, aiming to explore its potential as a monotherapy and in combination with other treatments, thereby offering new hope for targeted cancer treatment. This announcement marks a significant step forward in Shandong Boan Biotechnology's efforts to provide innovative cancer therapies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief on June 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shandong Boan Biotechnology Co. Ltd. Receives FDA Approval to Initiate Clinical Trials for BA1302 in the U.S</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShandong Boan Biotechnology Co. Ltd. Receives FDA Approval to Initiate Clinical Trials for BA1302 in the U.S\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-17 12:06</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Shandong Boan Biotechnology Co. Ltd. Receives FDA Approval to Initiate Clinical Trials for BA1302 in the U.S\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Shandong Boan Biotechnology Co. Ltd. has announced that it has received approval from the U.S. Food and Drug Administration (FDA) to initiate clinical trials for its novel antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>, BA1302, targeting CD228 for the treatment of various solid tumors. BA1302 has previously been granted Orphan Drug Designations by the FDA for squamous non-small cell lung cancer and pancreatic cancer. Currently, a Phase 1 clinical trial is ongoing in China, with development progress leading similar projects globally. The company is committed to accelerating the clinical development of BA1302 worldwide, aiming to explore its potential as a monotherapy and in combination with other treatments, thereby offering new hope for targeted cancer treatment. This announcement marks a significant step forward in Shandong Boan Biotechnology's efforts to provide innovative cancer therapies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief on June 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250617:nNDL9pqK1f:1","article_id":"2544090939","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544090939","pubTimestamp":1750133187,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Shandong Boan Biotechnology Co. Ltd. has announced that it has received approval from the U.S. Food and Drug Administration  to initiate clinical trials for its novel antibody-drug conjugate , BA1302, targeting CD228 for the treatment of various solid tumors. BA1302 has previously been granted Orphan Drug Designations by the FDA for squamous non-small cell lung cancer and pancreatic cancer. Currently, a Phase 1 clinical trial is ongoing in China, with development progress leading similar projects globally. The company is committed to accelerating the clinical development of BA1302 worldwide, aiming to explore its potential as a monotherapy and in combination with other treatments, thereby offering new hope for targeted cancer treatment. This announcement marks a significant step forward in Shandong Boan Biotechnology's efforts to provide innovative cancer therapies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT striv","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","BK1161":"生物科技","BK1606":"中医药概念","BK1191":"制药","02186":"绿叶制药","06955":"博安生物"},"translate_title":"山东博安生物科技有限公司获得FDA批准在美国启动BA1302临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02186":0.9,"06955":0.9},"content_text":"Shandong Boan Biotechnology Co. Ltd. Receives FDA Approval to Initiate Clinical Trials for BA1302 in the U.S\n    \n\n        Shandong Boan Biotechnology Co. Ltd. has announced that it has received approval from the U.S. Food and Drug Administration (FDA) to initiate clinical trials for its novel antibody-drug conjugate $(ADC)$, BA1302, targeting CD228 for the treatment of various solid tumors. BA1302 has previously been granted Orphan Drug Designations by the FDA for squamous non-small cell lung cancer and pancreatic cancer. Currently, a Phase 1 clinical trial is ongoing in China, with development progress leading similar projects globally. The company is committed to accelerating the clinical development of BA1302 worldwide, aiming to explore its potential as a monotherapy and in combination with other treatments, thereby offering new hope for targeted cancer treatment. This announcement marks a significant step forward in Shandong Boan Biotechnology's efforts to provide innovative cancer therapies.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief on June 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}